STAT+: Pharmalittle: We’re reading about a Novartis gene therapy, faster U.K. drug reviews, and more
Novartis acknowledged seven instances of tumors being found in children who were treated with Zolgensma for spinal muscular atrophy
Novartis has disclosed seven previously unknown instances of tumors found in children treated with its spinal muscular atrophy therapy. This alarming development has raised concerns among families, physicians, and patient advocacy groups. The cases, initially revealed by an advocacy group and subsequently shared on a Facebook page by the company, have prompted regulatory authorities to investigate further.
Four members of a U.S. health panel appointed by Health and Human Services Secretary Robert F. Kennedy Jr. in September have significant investments in companies affected by the panel's decisions. These individuals serve on the U.S. Preventive Services Task Force, which evaluates evidence for various health services and guides insurer payments.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
